Combination chemotherapy with TAS‑102 plus bevacizumab in salvage‑line treatment of metastatic colorectal cancer: A single‑center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage‑line therapy of metastatic colorectal cancer

Abstract

The combination regimen of TAS-102, a novel oral nucleoside antitumor agent containing trifluridine and tipiracil hydrochloride, with bevacizumab (C-TASK FORCE), a selective monoclonal antibody inhibitor of vascular endothelial growth factor-A, as salvage-line therapy for metastatic colorectal cancer (mCRC) was established based on its high clinical effectiveness. The aim of the present study was to evaluate the prognostic accuracy of the modified Glasgow Prognostic Score (mGPS) in patients receiving TAS-102 plus bevacizumab. The study included 17 patients (12 men and 5 women, mean age 60.4±13.4 years) with unresectable mCRC who were confirmed to have wild-type or mutant RAS genes. The patients received salvage-line treatment with TAS-102 plus bevacizumab at the Surgical Oncology

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab

“…In addition, grade 3 or 4 neutropenia occurred in 38.9-72.0% of all cases. The clinical outcomes of the present study were comparable to previous reports (11,14,(16)(17)(18)(19)(20). A summary of previous prospective and retrospective reports of FTD/TPI monotherapy for patients with mCRC is presented in Table SIII (5,6,(21)(22)(23)(24)(25)(26)(27)(28).…”

“…Moreover, clinical data from the phase I/II C-TASK FORCE study and the phase II study conducted by Pfeiffer et al (11,14) showed that treatment with FTD/TPI + Bev induced promising antitumor activity with manageable toxicity in advanced mCRC refractory or intolerant to standard therapies. A summary of previous prospective and retrospective reports of FTD/TPI + Bev FTD/TPI monotherapy (Tables ⅤI and SⅢ) (5,6,11,14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Furthermore, the clinical outcomes of FTD/TPI + Bev of this study were comparable to previous reports.…”

“…Thus, FTD/TPI + Bev may be a more effective regimen than FTD/TPI monotherapy. On the other hand, the incidence of grade 3 or 4 CIN of FTD/TPI + Bev is higher than FTD/TPI monotherapy (Tables ⅤI and SⅢ) (5,6,11,14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). CIN was an independent predictive factor for the efficacy of FTD/TPI monotherapy, as reported previously (11,(30)(31)(32).…”

“…The DCR in patients with grade 3 or 4 CIN within the first cycle of treatment was higher than in patients without grade 3 or 4 CIN (61.5 and 38.2%, P=0.07; Table Ⅲ). (11,14,(16)(17)(18)(19)(20). In these reports, the median PFS time was 3.7-6.8 months and the median OS time was 8.6-14.4 months.…”

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

“…Moreover, an investigator‐initiated, open‐label, single‐arm, multicenter, phase I/II study (C‐TASK FORCE) by Kuboki et al reported that the median PFS by investigator assessment was 5.6 months (95% CI, 3.4–7.6) and OS was 11.4 months (95% CI, 7.6–13.9) . We previously showed that, in salvage‐line therapy for patients with mCRC, Bmab enhances the antitumor effects of TAS‐102 with a median OS (14.1 months) and PFS (6.8 months) superior to those reported in the C‐TASK FORCE study . However, neither the C‐TASK FORCE study nor our previous report compared TAS‐102 alone and TAS‐102 plus Bmab, and the effect of Bmab in combination with TAS‐102 was confirmed in a limited number of patients with mCRC.…”